The Swiss pharma company Novartis ranks in the top 10 of pharma companies, and boasts drugs ranging from Ritalin and Lamisil to clozapine, Diovan and Gilenya. It also owns the generic giant Sandoz. Unlike its competitor, GlaxoSmithKline, Novartis did not offer free flu vaccines during the H1N1 flu epidemic.

In March 2011, Novartis gained FDA approval for Gilenya, its multiple sclerosis drug. The nod came on the heels of a narrower EMA approval, which grants second-line treatment status. According to experts, the drug could be worth $3 billion in annual sales as the first oral MS drug on the market.

Novartis purchased the remaining portion of eye care company Alcon in a $12.9 billion deal at the end of 2010, marking the end of one of the biggest battles in biopharma. Although many analysts predicted heavy layoffs in 2010 from the company, only 1,400 jobs were cut in December 2010, with the disclaimer that more could be on the way as Novartis, like others in the industry, analyzes its efficiency.

Tag:

Novartis

Latest Headlines

Latest Headlines

Novartis combo therapy for COPD shows promise in clinical trials, awaits FDA approval

Novartis announced that its investigational combination indacaterol/glycopyrronium bromide therapy for COPD performed better than its constituent components in a Phase III clinical trial.

Novartis' duo of COPD drugs clears Phase III on the path to an FDA decision

Novartis, working to get a pair of Europe-approved COPD treatments onto the U.S. market, reported some positive Phase III data while awaiting final word from the FDA.

Big Pharma's a C student, rep study finds, with Bayer at the top, Novartis at bottom

When it comes to Big Pharma's reputation, "average" says it all. That's the story from the research firm Reputation Institute, which perennially puts major drugmakers right smack in the middle of its scorecard. In other words, pharma is a C student.

33 indicted for selling BMS' Abilify, Novartis' Gleevec in massive diversion scheme

Federal authorities have rounded up nearly three dozen people indicted in a far-ranging scheme in which they allegedly sold $200 million worth of diverted drugs that included blockbusters like Bristol-Myers Squibb's antipsychotic Abilify, Gilead Sciences' HIV med Truvada and Novartis' cancer drug Gleevec.

Novartis' Sandoz expands Poland plant with packaging facility

Novartis' plant in Stryków, Poland, one of the largest of its Sandoz generics unit, had no packaging lines, forcing the company to transport its production to other facilities for that step in the supply chain. Sandoz will be able to expand capacity at the plant and save on transportation costs now that it has opened a new packaging facility there.

Novartis grabs Zykadia approval in Europe, setting the stage for showdown

Novartis' Zykadia picked up some steam in its head-to-head rivalry with Pfizer's Xalkori, snagging EU approval and setting the stage for a showdown as the companies compete for top dog.

Court blocks Novartis' biosimilar copy of Amgen's Neupogen

Amgen is none too eager for Novartis to roll out its newly FDA-approved biosimilar version of its blockbuster Neupogen, and for now, it's getting its way: A U.S. appeals court has blocked sales of the copycat while the companies resolve a patent dispute.

Big Pharma's cardiovascular sales ain't what they used to be

Slumping sales for cardiovascular drugs isn't exactly a new phenomenon for Big Pharma, with some of the industry's top drugmakers suffering from recent patent expirations. But a new report shows which CV franchises have been hurt the most. 

Oxford BioMedica takes out $50M loan to service Novartis CAR-T alliance

Oxford BioMedica has secured a $50 million (€45 million) loan, half of which it will take out immediately to expand its laboratory and manufacturing facilities. The first tranche of money will help OXB service its CAR-T alliance with Novartis.

GSK weighing scrapping investor payout to boost dividend instead

Analysts are suggesting that GlaxoSmithKline is thinking hard about scrapping a plan to reward investors by paying them about £4 billion and instead use money from its deals with Novartis to prop up its dividend, Reuters reports.